ATG4B and hepatocellular carcinoma: Although a number of autophagy-targeted interventions such as Lys05, HSF1/ATG4B knockdown, and ADCX have been reported to sensitize HCC cells to doxorubicin11–13, clinically beneficial autophagy modulations against doxorubicin resistance in HCC patients are still rare and need further exploration.